TrialNature communications2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.
Joonil Jung et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
61 papers cite itlatest 60 shown
this paperpooled ittrialcites it